Last updated: 2023-09-12 If you’re used to buying shares on the stock market, it doesn’t have to be a big leap to invest in unlisted companies as well. At Sciety, we frequently receive questions from people who are considering making their first investment in an unlisted company. Practically speaking, how
Neurological disorders have been pinpointed by WHO as one of the greatest threats to public health. As an example, nearly 10 million people develop dementia each year and the number of people living with dementia is expected to triple from 50 million to 152 million by 2050. Today, the annual
Sciety becomes a member in the trade association SwedenBIO that works for a strong life science sector in Sweden. The members include micro companies to big pharma but also companies that provide services in business development, IP, financing and etc. As Sciety works with financing of unlisted companies, in the
The new issue of shares in EMPE Diagnostics was fully subscribed already two weeks before the subscription period expired. EMPE Diagnostics develops a rapid test for diagnosis of tuberculosis. In total, 10 million SEK was invested and the funding will be used for final product validation and market launch.
Last week, the trade associations LIF, Swedish Medtech and SwedenBIO presented an action plan to strengthen the competitiveness of Swedish life science. As Sciety meets many companies that develop the healthcare sector, we find it is very interesting that one of the three topics in the plan is to introduce
Sciety closes a financing round of 10 million SEK and welcomes thirty new shareholders with backgrounds in the finance and healthcare sectors. The largest investor is the investment company Linc. Sciety is an investment platform focusing on unlisted growth companies in the healthcare sector. Since Sciety’s launch during the autumn